| Selectivity Comparison of Tumor-Imaging Probes Designed Based on Various Tumor-Targeting Strategies: A Proof of Concept Study. | Selectivity Comparison of Tumor-Imaging Probes Designed Based on Various Tumor-Targeting Strategies: A Proof of Concept Study.
Guo RY, Wang HM, Dong X, Hu Y, Li J, Zang Y, Li X. | 04/2/2022 |
| The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. | The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. | 11/27/2021 |
| Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. | Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
Soukup J, Hornychova H, Manethova M, Michalova K, Michnova L, Popovska L, Skarkova V, Cesak T, Netuka D, Ryska A, Cap J, Hána V, Hána V Jr, Kršek M, Dvořáková E, Krčma M, Lazurova I, Olšovská V, Starý K, Vaňuga P, Gabalec F., Free PMC Article | 09/25/2021 |
| High SSTR1 expression is associated with hepatocellular and cholangiocellular carcinomas in tumor capillaries. | Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A., Free PMC Article | 08/18/2018 |
| Data showed that the distribution of somatostatin receptor (SSTR) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (54.8%), SSTR1 (53.3%), SSTR4 (51.8%), SSTR5 (33.7%), and SSTR3 (28.6%). | Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
Song KB, Kim SC, Kim JH, Seo DW, Hong SM, Park KM, Hwang DW, Lee JH, Lee YJ. | 10/22/2016 |
| An immunohistochemical investigation of the expression of somatostatin receptor subtypes | An immunohistochemical investigation of the expression of somatostatin receptor subtypes - should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?
Pisarek H, Pawlikowski M, Marchlewska M, Minias R, Winczyk K. | 03/12/2016 |
| Aberrant methylation inactivates somatostatin and SSTR1 in head and neck squamous cell carcinoma. | Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K, Misawa Y, Kondo H, Mochizuki D, Imai A, Fukushima H, Uehara T, Kanazawa T, Mineta H., Free PMC Article | 01/23/2016 |
| The UMB-7 may prove of great value in the identification of sst1-expressing tumors during routine histopathological examinations. This may open up new routes for diagnostic and therapeutic intervention. | Reevaluation of sst₁ somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7.
Lupp A, Nagel F, Schulz S. | 10/3/2015 |
| SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management. | Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.
Buder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, Bröcker EB, Goebeler M, Buck AK, Becker JC., Free PMC Article | 12/20/2014 |
| SSTRs are overexpressed in primary pigmented nodular adrenocortical disease tissues in comparison with normal adrenal cortex | Does somatostatin have a role in the regulation of cortisol secretion in primary pigmented nodular adrenocortical disease (ppnad)? a clinical and in vitro investigation.
Bram Z, Xekouki P, Louiset E, Keil MF, Avgeropoulos D, Giatzakis C, Nesterova M, Sinaii N, Hofland LJ, Cherqaoui R, Lefebvre H, Stratakis CA., Free PMC Article | 07/12/2014 |
| Activated/phosphorylated pMAPK 44/42 was detected in 82% of medulloblastomas, all subtypes, and in 62.5% of primitive neuroectodermal tumors with coexpression of SSR1 in one third. | Differential expression of somatostatin receptors, P44/42 MAPK, and mTOR activation in medulloblastomas and primitive neuroectodermal tumors.
Johnson MD, O'Connell MJ, Silberstein H, Korones D. | 06/14/2014 |
| Somatostatin receptor imaging (SRI) using SPECT or PET as a whole-body imaging technique has become a crucial part of the management of Neuroendocrine tumors | Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.
Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H., Free PMC Article | 06/7/2014 |
| Tumor cells in the tissue samples of the patients diagnosed with advanced-stage hepatocellular carcinoma expressed a high proportion of SSTR1 and SSTR5. | Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma.
Koc EU, Ozgur T, Yerci O, Gurel S. | 04/12/2014 |
| Somatostatin receptor 1 is a novel methylated gene driven by EBV infection in gastric cancer cells and acts as a potential tumour suppressor. | Somatostatin receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer.
Zhao J, Liang Q, Cheung KF, Kang W, Dong Y, Lung RW, Tong JH, To KF, Sung JJ, Yu J., Free PMC Article | 09/14/2013 |
| Data demonstrate that cells transfected with SSTR1 or SSTR1/5 negatively regulates EGF mediated effects attributed to the inhibition of EGFR phosphorylation. | Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. | 07/30/2011 |
| Data show that the mRNA levels of SSTR1, SSTR2, SSTR3, and SSTR5 were high in PET compared with AC, whereas the expression of SSTR4 was low in PET and AC. | Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors.
Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi S. | 03/5/2011 |
| Studies show that this study may be the basis for further functional studies to evaluate the role of somatostatin receptors sst1 to sst5 in the diabetic state. | Somatostatin receptor subtypes in human type 2 diabetic islets.
Portela-Gomes GM, Grimelius L, Westermark P, Stridsberg M. | 02/5/2011 |
| Overexpressed in endomterium inendometriosis. | Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions.
Fasciani A, Quilici P, Biscaldi E, Flamini M, Fioravanti A, Orlandi P, Oliviero J, Repetti F, Bandelloni R, Danesi R, Simoncini T, Bocci G. | 01/15/2011 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X., Free PMC Article | 12/5/2010 |
| The summarized expression pattern of SSTR in the investigated neuroendocrine tumors in our material was: SSTR 1> SSTR 5> SSTR 3> SSTR 2A> SSTR 2B. | SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K. | 09/20/2010 |
| Meta-analysis of gene-disease association. (HuGE Navigator) | Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.
Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanché H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, DeLancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Hüsing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjønneland A, Trichopoulos D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS., Free PMC Article | 09/15/2010 |
| SSTR1 had higher expression in patients that had normalized GH and IGF-I. There was a positive correlation between the percentage of tumor reduction by octreotide-lar and SSTR1 expression. | Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD. | 02/8/2010 |
| Both SSTR1 and 2 mRNA levels in SCA were greater than Cushing disease, while SSTR1 mRNA levels, but not SSTR2, in silent corticotroph adenoma were also greater than non-functioning pituitary tumor. | Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. | 01/21/2010 |
| An autocrine and paracrine role of SST in the lacrimal system and at the ocular surface and a role of SST in corneal immunology. | Somatostatin actions via somatostatin receptors on the ocular surface are modulated by inflammatory processes.
Minsel I, Mentlein R, Sel S, Diebold Y, Bräuer L, Mühlbauer E, Paulsen FP. | 01/21/2010 |
| To the best of our knowledge, this is the first report describing crosstalk/interactions between SSTRs and ErbBs. | Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.
Watt HL, Kharmate GD, Kumar U. | 01/21/2010 |